Direct interaction between estrogen receptor α and NF-κB in the nucleus of living cells

Molecular and Cellular Endocrinology

Volumn 273, Issue 1-2, 2007, Pages 42-50

  Quaedackers, Monique E ^a   van den Brink, Christina E ^a   van der Saag, Paul T ^a   Tertoolen, Leon G J ^a  

^a HUBRECHT INSTITUTE   (Netherlands)

Author keywords

ER ; FRET; In vivo; Interaction; NF B

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; STEROID RECEPTOR; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR REL;

ARTICLE; CELL NUCLEUS; DELETION MUTANT; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CLONE CELLS; ESTROGEN RECEPTOR ALPHA; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; IMMUNOPRECIPITATION; LUMINESCENT PROTEINS; NF-KAPPA B P50 SUBUNIT; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC;

EID: 34347333594     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.05.002     Document Type: Article

References (31)

1. Baldwin Jr. A.S. Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 107 (2001) 3-6
2. Blanchetot C., Tertoolen L.G., and den Hertog J. Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress. EMBO J. 21 (2002) 493-503
3. Caldenhoven E., Liden J., Wissink S., van de Stolpe A., Raaijmakers J., Koenderman L., Okret S., Gustafsson J.A., and van der Saag P.T. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol. 9 (1995) 401-412
4. Chadwick C.C., Chippari S., Matelan E., Borges-Marcucci L., Eckert A.M., Keith Jr. J.C., Albert L.M., Leathurby Y., Harris H.A., Bhat R.A., Ashwell M., Trybulski E., Winneker R.C., Adelman S.J., Steffan R.J., and Harnish D.C. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2543-2548
5. Chen F.E., Huang D.B., Chen Y.Q., and Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA. Nature 391 (1998) 410-413
6. Chen L.F., and Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 5 (2004) 392-401
7. De Bosscher K., Van Den Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24 (2003) 488-522
8. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann. N.Y. Acad. Sci. 1024 (2004) 124-137
9. Harnish D.C., Scicchitano M.S., Adelman S.J., Lyttle C.R., and Karathanasis S.K. The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology 141 (2000) 3403-3411
10. Hodgin J.B., and Maeda N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 143 (2002) 4495-4501
11. Kalaitzidis D., and Gilmore T.D. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol. Metab. 16 (2005) 46-52
12. Kalaitzidis D., Ok J., Sulak L., Starczynowski D.T., and Gilmore T.D. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene 23 (2004) 7580-7587
13. Kalkhoven E., Wissink S., Van Der Saag P.T., and Van Der Burg B. Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor. J. Biol. Chem. 271 (1996) 6217-6224
14. Kim K., Barhoumi R., Burghardt R., and Safe S. Analysis of estrogen receptor alpha-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. Mol. Endocrinol. 19 (2005) 843-854
15. Llopis J., Westin S., Ricote M., Wang J., Cho C.Y., Kurokawa R., Mullen T.M., Rose D.W., Rosenfeld M.G., Tsien R.Y., and Glass C.K. Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4363-4368
16. Luecke H.F., and Yamamoto K.R. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev. 19 (2005) 1116-1127
17. McKay L.I., and Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappaB and steroid receptor-signaling pathways. Endocr. Rev. 20 (1999) 435-459
18. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., and Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
19. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet Jr. R.J., and Sledge Jr. G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 17 (1997) 3629-3639
20. Nissen R.M., and Yamamoto K.R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 14 (2000) 2314-2329
21. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J.A., Kushner P.J., and Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ER at AP1 sites. Science 277 (1997) 1508-1510
22. Pfeilschifter J., Koditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23 (2002) 90-119
23. Pollok B.A., and Heim R. Using GFP in FRET-based applications. Trends Cell Biol. 9 (1999) 57-60
24. Quaedackers M.E., van den Brink C.E., Wissink S., Schreurs R.H., Gustafsson J.A., van der Saag P.T., and van der Burg B. 4-hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta. Endocrinology 142 (2001) 1156-1166
25. Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G., Gustafsson J.A., and Safe S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 275 (2000) 5379-5387
26. Stein B., and Yang M.X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell Biol. 15 (1995) 4971-4979
27. Turgeon J.L., McDonnell D.P., Martin K.A., and Wise P.M. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304 (2004) 1269-1273
28. Wang D., and Baldwin J. Activation of nuclear factor-kappa b-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273 (1998) 29411-29416
29. Wissink S., van Heerde E.C., Schmitz M.L., Kalkhoven E., van der Burg B., Baeuerle P.A., and van der Saag P.T. Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J. Biol. Chem. 272 (1997) 22278-22284
30. Xia Z., and Liu Y. Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscopes. Biophys. J. 81 (2001) 2395-2402
31. Yamasaki D., Enokida M., Okano T., Hagino H., and Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 28 (2001) 634-640